Oncology
Researchers provide details of new studies and findings in the area of oncology
Published in Hepatitis Weekly, July 4th, 2005
Study 1: Regulatory T cells in liver cancer patients may hinder cancer immunotherapy.
According to recent research published in the journal Cancer Research, "hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor prognosis and one for which immunotherapy remains a viable option. Experimental tumor models have shown that regulatory T cells, a functionally unique subset of T cells, can suppress effective antitumor immune responses. This suppression might explain the poor outcome of some of the immunotherapy protocols currently being used."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-07-04)
More Articles from Hepatitis Weekly
- Adverse Drug Reaction
Patients with interferon-induced Graves disease fare better than others - Diagnostics
IgM anti-hepatitis C virus titers divulge the threat of acute hepatitis - Hepatocellular Carcinoma
Murine liver tumors respond to combined suicide-cytokine gene therapy - Vaccine Development
Immunostimulatory adjuvant may be key to hepatitis C vaccine efficacy - Vaccine Development
Oligonucleotide prototype boosts immunological response to hepatitis B vaccine - Addiction Medicine
MELD scores are superior predictors of alcoholic hepatitis related mortality - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
